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CME
The cover photo shows the image of the HPV virus. Most of the cervical cancers 
and pre-malignant diseases are related to the infection of this high risk HPV, for 
example, HPV types 16 and 18. By understanding its basic epidemiology and 
microbiology, we can mount strategies to control and prevent cervical cancers, 
namely, primary prevention by HPV vaccination, secondary prevention by 
cervical cytology (+/- HPV DNA test) and lastly early referral of diseased 
patients for treatment (colposcopy, LEEP and/or cancer treatment).
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Editorial 
Dr. Siu-keung LAM
The Hong Kong Society for Colposcopy and Cervical Pathology was 
inaugurated in 2000 under the leadership of the founding President, 
Professor Hextan NGAN. I was the third President after Professor 
Annie CHEUNG. The aim of the Society is to enhance the knowledge 
and skill in cervical cancer prevention, organise regular educational 
activities for our members, doctors, nurses and laboratory staff. 
In conjunction with the Hong Kong College of Obstetricians and 
Gynaecologists, accreditation exercises are organised for specialist 
colposcopists and refresher courses on colposcopy are held regularly. 
The Society also accredits nurses as smear takers after completion of the 
relevant theoretical and practical training. 
The field of colposcopy and cervical cancer screening has undergone 
many changes in the past 12 years. First and foremost was the 
availability of HPV vaccines as primary prevention. Although the uptake 
of HPV vaccines is relatively slow probably because of the cost, more 
and more parents are willing to bring their young kids for vaccination. 
Only with a high coverage rate then can we be able to decrease the 
cervical cancer incidence further. In her paper, Dr. Assumpta WONG 
discussed the rationale and efficacy of the 2 HPV vaccines used in Hong 
Kong. Without a proper understanding of the relationship between 
HPV and cervical cancer, it will be difficult to link the HPV infection, 
co-carcinogens and the gradual deterioration of cervical premalignant 
changes to malignant changes. Prof. Annie CHEUNG in her paper gave 
a very detailed explanation on the epidemiology and pathophysiology 
of the cervical malignant transformation and the current method for 
detection be it by cytology or by molecular tests. 
The secondary prevention by regular Pap smears (cytology) is the 
cornerstone of the conventional cervical cancer screening programme. 
The addition of HPV DNA test either as a reflex test or co-test (cytology 
and HPV DNA at the same time) was further proven to improve the 
sensitivity and specificity of cervical cancer detection. I described some 
of the recent advances in the screening methodology abroad particularly 
in USA and the Netherlands. The screening strategy will obviously 
be different in different localities e.g. Hong Kong, China Mainland or 
Africa, depending on the HPV incidence, HPV epidemiology, disease 
burden, patient availability and most important of all the medical 
infrastructure. 
The last defence will be the early referral of patients with abnormal 
smears and/ or abnormal looking cervixes for colposcopy and/ or 
cervical cancer treatment. Dr. Mandy CHU and Dr. Karen CHAN 
described the updates in the management of abnormal smears in 
Hong Kong and Dr. SF YIM of The Chinese University of Hong Kong 
highlighted some of the recent advances in the management of cervical 
cancer. 
The ultimate objective of the Society is to decrease the incidence of 
premalignant and malignant diseases of the cervix thus improving the 
quality of life of women at large. 
Editor
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Updates on Cervical Cancer Screening and 
Management of Abnormal Cervical Smears
Dr. Siu-keung LAM
President, Hong Kong Society for Colposcopy and Cervical Pathology
Specialist in Obstetrics and Gynaecology
Introduction
In 2008, cervical cancer was the tenth most common 
cancer among women in Hong Kong.  According to 
the Hong Kong Cancer Registry, there were 358 new 
cases of cervical cancer, accounting for 3.1% of all new 
cancer cases in females.  The crude incidence rate was 9.7 
per 100 ,000 female population.  The age-standardised 
incidence rate was 6.9 per 100, 000 standard population. 
The median age at diagnosis was 53 years old.  In 2009, 
cervical cancer was the ninth most common female 
cancer death.  There were 128 deaths in females due 
to this cancer, accounting for 2.5% of all cancer deaths 
in females.  In 2009, the crude death rate was 3.5 per 
100 ,000 female population and the age-standardised 
mortality rate was 2.2 per 100 ,000 standard population. 
The incidence was gradually decreasing over the years 
probably because of the increasing cervical smear 
screening coverage. 
Screening strategy
Before the establishment of the government’s cervical 
smear screening programme opportunistic screening 
had already been carried out. Patients attending 
private doctors, family planning clinics, gynaecology 
clinics, antenatal clinics and emergency gynaecology 
admissions were offered cervical smears but not in an 
organised manner. Patients will not be called back on a 
regular basis except for those having abnormal smears. 
Colposcopy examinations were not widely available in 
the government hospitals as in the present situation. 
In March 2004 the Department of Health, in collaboration 
with other health care professionals, started to organise 
the Cervical Smear Screening Programme (CSSP) to 
facilitate and encourage women to have regular cervical 
smears with the ultimate aim of decreasing the incidence 
of cervical cancer in Hong Kong. 
The programme objectives include:
1. To raise public awareness on the need for cervical 
cancer screening; 
2. To improve the overall coverage of the target 
population; 
3. To promote more equitable and efficient screening 
across the target population. 
4. To build a quality assurance mechanism for 
better quality screening services in smear-taking, 
cytological examinations, referrals and follow-up 
management of abnormal smears; and 
5. To provide better support to the private sector and 
relevant stakeholders 
The screening protocol proposed by the Department 
of Health and Hong Kong College of Obstetricians and 
Gynaecologists was simple: cervical smear screening 
from the age of 25 with the first two smears one year 
apart, then three yearly thereafter. The screening can be 
stopped at the age of 65 if the latest three smears were 
all negative. Women over 65 should have at least one 
smear if never done before.  Women with no sexual 
experience or women having had hysterectomy can be 
excluded from the programme. A flowchart is enclosed 
for your reference.1
Figure 1: The screening flowchart recommended by Department of 
Health
Please note this protocol refers to healthy women 
and the frequency of cervical smear screening can 
be increased in patients with abnormal smears, after 
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treatment and clinically suspicious cases. 
Other than the publicity and promotion on cervical smear 
screening, the Department of Health also collects useful 
data on the number of clients having regular cervical 
smears in Hong Kong. Up till now there are 436,461 
clients recorded in the Cervical Screening Information 
System (but please note that the reporting is voluntary 
and the total number of clients having cervical smears in 
Hong Kong is more than this number). 
Figure 2: Cumulative total number of women registered with the 
Cervical Smear Screening Programme (total: 436461, source from 
Department of Health)
The age range of the clients in the Cervical Screening 
Information System is shown in the chart below with 
the majority of women in the reproductive age group. 
Although the screening should start at the age of 25, a 
small proportion of clients have cervical smears under 
the age of 25 because of other risk factors e.g. multiple 
partners, smokers etc. 
Figure 3: Number of women registered with the Cervical Smear 
Screening Programme by Age group (total = 436 461, source  from 
Department of Health)
Since the establishment of the government’s cervical 
smear screening programme in 2004, the average 
coverage rate (i.e. women with cervical smear screening 
in their previous three years) was also analysed. It 
seems the average rate has reached a plateau of 60% and 
health care workers may need to work hard to reach 
the remaining at risk population. Only by increasing 
the population screening, we can aim to decrease the 
incidence of malignant and premalignant cervical 
lesions. The target objective is to reach 80% of the at risk 
population.
 
Figure 4: Percentage of respondents with last cervical smear taken 
within three years with the latest figure plateau at 60%
The method for cervical cancer screening
Conventional Pap smear taking is by taking cervical cells 
by the wooden Ayre spatula and spreading on a glass 
slide and fixed by alcohol or other fixatives. The liquid 
base cytology (LBC) has almost completely replaced the 
conventional glass slide in Hong Kong as the latter’s 
unsatisfactory rate is lower and the quality of smear 
is better and easier to be read by the pathologist. As 
some of the laboratory procedure can be automated, the 
turnaround time can be shortened. The remaining aliquot 
can be used for HPV DNA testing if needed without 
calling back the patient for another sample (reflex testing)
Figure 5: the traditional glass slide and wooden spatula on the left 
hand side and the plastic brush and liquid base cytology bottle on 
the right hand side (preferred method for collection)
HPV DNA tests were used in the triage of low 
grade smears (i.e. refer for immediate colposcopy or 
observation), test of cure after LEEP (loop electrosurgical 
excision procedure) and co-testing in the past but its 
role is now further widened with more reliable HPV 
DNA tests. The current HPV genotyping test is able 
to differentiate each type of the high risk HPV DNA 
e.g. HPV 16 or HPV 18 as compared with the previous 
basket test (Digene test which indicated presence of 
high risk HPV but will not specify which type).
As there are many new HPV DNA test kits available, 
clinicians should be careful in the selection of the test 
kits and the interpretation of the results. 
Management of abnormal cervical 
smears in Hong Kong
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Patients with abnormal cervical smears will be managed 
according the recommended protocol of the Hong Kong 
College of Obstetricians and Gynaecologists. Basically 
for low grade lesions, observation is the norm especially 
for young patients. For high grade abnormality CIN 
II or III, excision treatment (LEEP) under LA or GA is 
recommended. Some clinicians may elect a see and treat 
policy in selected cases. Cryotherapy and LASER treatment 
(ablative treatment) are not much used nowadays. 
Changes in the screening methodology
The screening strategy will be different in different 
countries according to the local disease prevalence, HPV 
epidemiology and medical infra-structure. 
There are recent updates on the screening strategy that 
may be worthwhile for Hong Kong to consider:
Co-testing rather than pap smear alone
In the POBASCAM trial 2 45,000 women aged 29 to 
56 years attending routine cervical screening in the 
Netherlands between 1999 and 2002, were equally 
randomised to receive either HPV DNA testing and 
cytology or cytology alone. The researchers wanted to see 
if HPV testing would result in fewer high grade lesions 
and cancers in the second round of screening 5 years later 
because of earlier detection and treatment of lesions after 
the first round. They then assessed the most appropriate 
age for starting HPV testing. In the second round, HPV 
testing and cytology were done on all women.
In the first screening, HPV testing identified significantly 
more cancer precursors (CIN 2 or worse) than cytology 
alone (267/19999 vs 215 /20106, p=0.015) Five years later, 
significantly fewer women had CIN grade 3 or worse 
(88/19579 vs 122/19731, p= 0.023) and cervical cancers 
(4/19579 vs 14/19731, p=0.031) in the HPV group, 
compared with cytology alone. 
HPV DNA testing definitely has a role in the cervical 
cancer screening because of its higher sensitivity but 
how it can be incorporated in the screening strategy 
in Hong Kong has yet to be decided. Nevertheless 
the American Cancer Society, American Society for 
Colposcopy and Cervical Pathology and American 
Society for Clinical Pathology all  have already 
recommended changes to the screening strategy for 
women aged 30 to 65 as follows: 3
(1) HPV and cytology co-testing every five years 
(preferred method for routine screening)
Group (A): if HPV positive, and cytology ASCUS and 
>= LGSIL, consider colposcopy
Group (B): if HPV positive, cytology negative 
Option (1) 12 month follow ups with 
co-testing
Option (2) Test for HPV 16 or HPV 16/18 
genotype
If HPV 16 or HPV 16/18 positive, refer for 
colposcopy
If HPV 16 or HPV 16/18 negative, 12 
month follow ups with co-testing
Group (C): Co-test negative or HPV negative ASCUS, 
rescreen with co-testing in 5 years
Definition: Co-test: cytology and HPV DNA test at the same   
                     time (same specimen)
ASCUS = Atypical squamous cells of unknown significance
LGSIL = Low grade intraepithelial neoplasia 
(2) Cytology alone every three years (acceptable)
Patients with normal smears but positive HPV DNA 16 
or 16/18 might be put on cytology surveillance in the 
past but some recent studies showed that this group of 
patients having the HPV 16 and or 18 (i.e. the two most 
oncogenic viruses) may harbour a significant risk of CIN 
and cancer. The 12 month risk for CIN 3+ following an 
HPV-positive cytology-negative co-test ranged from 
0.8%4 to 4.1%5. The estimated 12-month risk of cancer 
was 0.08%4. The consensus group therefore recommends 
immediate colposcopy for patients with positive HPV 
16 or  positive HPV 16/18 even if the smear is negative. 
If immediate colposcopy is not feasible, than repeat co-
testing in 12 months’ time. 
HPV DNA as primary screening
HPV DNA as primary screening is not widely used 
in the world except the Netherlands where they will 
change to primary HPV DNA screening starting from 
age 30 and cytology as back up (reflex cytology, if 
cytology abnormal, refer for colposcopy). The number 
of colposcopy will be unacceptably high if all HPV 
positive women are referred for colposcopy. The result 
of the new screening strategy of the Netherlands will be 
useful for other countries in adopting a new screening 
paradigm (from the gold standard cytology which was 
used for 50 years to the HPV DNA test). There are even 
suggestions to send the patients a kit to take vaginal 
swab for HPV DNA at home to increase the uptake rate 
(patient self collection). 
Conclusion
Without a national HPV vaccination programme, it 
will be unlikely for Hong Kong to cover a significant 
proportion of males and females and the reduction on 
the cervical cancer incidence will take a long time to be 
achieved. We should therefore rely on a reliable cervical 
screening strategy most likely a combination of cytology 
and HPV DNA test (exact model which is suitable 
for our locality to be worked out). Prompt referrals to 
colposcopy and/or cancer treatment will further reduce 
the incidence of cervical cancers on a long run. 
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MCHK CME Programme Self-assessment Questions
Please read the article entitled “Updates on Cervical Cancer Screening and Management of Abnormal Cervical 
Smears” by Dr. Siu-keung LAM and complete the following self-assessment questions. Participants in the MCHK 
CME Programme will be awarded CME credit under the Programme for returning completed answer sheets via fax 
(2865 0345) or by mail to the Federation Secretariat on or before 31 December 2012. Answers to questions will be 
provided in the next issue of The Hong Kong Medical Diary. 
1. The number of death due to cervical cancer in Hong Kong was around 300 each year 
2. The current coverage rate for cervical smear screening in HK was 80% 
3. Almost all the cervical cancer is related to HPV infection
4. Women with hysterectomy should have regular smear after the operation still 
5. The liquid base cytology LBC is the preferred method for cells collection
6. HPV DNA tests can be done in the same specimen (bottle) for cervical smear
7. The most common treatment for cervical intraepithelial neoplasia is cryotherapy 
8. The POBASCAM trial showed HPV DNA tests and cytology was better than cytology alone 
9. Co-testing referred to the combination of cytology and HPVDNA test together 
10. In Netherlands, HPV DNA tests will be used as primary screening with cytology as adjunct 
Questions 1-10: Please answer T (true) or F (false) 
ANSWER SHEET FOR DECEMBER 2012
Answers to November 2012 Issue
Please return the completed answer sheet to the Federation Secretariat on or before 31 December 2012 for 
documentation. 1 CME point will be awarded for answering the MCHK CME programme (for non-specialists) self-
assessment questions.
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HPV Vaccine Updates
Dr. Assumpta SM WONG 
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Introduction 
Cancer of the cervix is the second most common cancer 
in women worldwide, with about 500 000 new cases and 
250 000 deaths each year1. Almost 80% of cases occur in 
low-income countries. In Hong Kong, there were 453 
new cases of cervical cancer and 128 cases of mortality 
resulted from the disease in the year 20092. Virtually 
all cervical cancer cases (99%) are linked to genital 
infections with the human papillomavirus (HPV).
HPV are DNA viruses that infect skin or mucosal cells. 
There are more than 100 known HPV genotypes, at least 
15 of which   (HPV-16,-18,-31,-33,-35,-39,-45,-51,-52,-56,-
58,-59,-68,-73 and -82) can cause cancer of the cervix and 
are associated with other anogenital cancers; they are 
called “high-risk” genotypes. The two most common of 
these (genotypes 16 and 18) cause approximately 70% of 
all cervical cancers. HPV (especially genotypes 6 and 11) 
also cause genital warts, a common benign condition of 
the external genitalia that causes significant morbidity. 
HPV vaccines
Two prophylactic HPV vaccines were launched and 
licensed since 2006 with the aim of preventing high risk 
HPV infections and cervical precancerous lesions by 
inducing high level of serum neutralising antibodies. 
They are prepared from virus-like particles (VLPs) that 
do not contain any live biological product or DNA, 
and so are   non-infectious. A quadrivalent vaccine 
(Gardasil®, which protects against high risk HPV types 
16 and 18, and low risk HPV types 6 and 11) and a 
bivalent vaccine (Cervarix®, which mainly protects 
against high risk HPV types 16 and 18) are currently 
available in the market. 
 
Efficacy
Both vaccines showed high efficacy (>90%) against 
HPV-16/18 related high grade cervical intraepithelial 
neoplasia (CIN) and adenocarcinoma in situ (AIS), 
which served as the surrogate endpoint of analysis. 
The overall efficacy of the bivalent vaccine against 
CIN3+ (CIN3 and AIS) was 100% (for HPV16/18 
associated lesion) and 93.2% (irrespective of HPV 
type in the lesion, including lesion with no HPV DNA 
detected), for women aged 15-25 years who have no 
evidence of HPV infection at baseline. In women who 
has unknown HPV DNA status and cervical cytology 
at baseline (including those who are sexually active 
and have received at least one vaccine dose) the efficacy 
of preventing CIN 3+ lesion was 45.7% for HPV16/18 
associated lesions and 45.6% irrespective of HPV type3. 
One study of the quadrivalent vaccine demonstrated 
an efficacy of 99% protection against HPV16/18 related 
CIN2/3, AIS or cervical cancer in women who were 
HPV DNA 16/18 negative at baseline and had received 
all three doses of vaccine4. The efficacy against vaccine-
related VIN 2-3 or VAIN2-3 was 95.4% and vaccine 
related genital warts was 96.4%5. 
Cross protection
Non-vaccine HPV types account for ~30% of cervical 
cancers; cross protection against these types would 
potentially enhance primary cervical cancer prevention.
Vaccine efficacy of the bivalent vaccine against CIN2+ 
associated with the composite of 12 non-vaccine HPV 
types (31,33,35,39,45,51,52,56,58,59,66 and 68), with or 
without HPV-16/18 co-infection, was 46.8% in those who 
received all 3 doses of vaccine and 56.2% in those who 
received at least one vaccine dose and were HPV naïve 
at baseline. The corresponding figure of efficacy after 
excluding HPV 16/18 co-infection was 24.1% and 17.1% 
respectively.6
For the quadrivalent vaccine, the study showed 
that there was a 32.5% reduction in CIN2+ lesions 
associated with 10 non-vaccine HPV types (HPV 
31,33,35,39,45,51,52,56,58,59), other than HPV type 16 
and 18, in women who were negative for the HPV tested 
at baseline7.
Immunogenicity and duration of 
protection
Antibodies  against  vaccine-related HPV were 
persistently high and remained at or several fold above 
those following natural infections after 5-9.4 years8-10. 
Mathematical modelling studies predicts that both 
vaccines would have a high and sustained antibody 
level for at least 20 years.11,12
A recent  s tudy compar ing  the  2  vacc ines  for 
immunogenicity in women who were seronegative and 
DNA-negative at baseline (for the HPV type analysed), 
Dr. William WH LIDr. Assumpta SM WONG 
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seropositivity rates of neutralising antibodies were 
across all age strata, 100% (HPV-16/18 vaccine) and 
97.5-100% (HPV-6/11/16/18 vaccine) for HPV-16, and 
99.0-100% (HPV-16/18 vaccine) and 72.3-84.4% (HPV-
6/11/16/18 vaccine) for HPV-18. The neutralising 
antibody level at 24 months was 2.4-5.8-fold higher 
for HPV-16 and 7.7-9.4-fold higher for HPV-18 with 
the bivalent vaccine versus the quadrivalent vaccine13. 
However, there are no data correlating antibody titres 
or memory B-cell response with clinical efficacy. 
Target population 
The quadrivalent vaccine (Gardasil®) is a vaccine 
indicated in girls and women from the age of 9 years 
through 45 years. It is indicated in boys and men from 
the age of 9 through 26 years for the prevention of 
genital warts. The efficacy of prevention against vaccine 
related (HPV6/11/16/18) anogenital warts and penile/ 
perineal/ perianal intraepithelial neoplasia was 89.4% 
and 100% respectively for those who have received all 
three vaccinations and were HPV naïve at baseline14.
The bivalent vaccine (Cervarix®) is a vaccine for use 
from the age of 9 years onwards.
Safety
Currently available data showed that both vaccines 
are safe. Injection site reactions, headache, syncope, 
nausea, vomiting, diarrhoea, abdominal pain, itchiness, 
rash, urticaria, myalgia, arthritis, fatigue and fever are 
the most frequently reported adverse effects for both 
vaccines. They are usually transient and do not affect 
compliance with the three-dose vaccination schedules15. 
A study of vaccine safety carried out in Hong Kong 
showed that the vaccine (bivalent vaccine) was well 
tolerated and compliance was high (99%). Pain was the 
most common local symptom while fatigue and myalgia 
were the most frequent general symptoms. There 
was no serious adverse event that was related to the 
vaccination16. 
Psychosocial issues
The acceptance of the vaccine plays a key role in cervical 
cancer prevention. HPV knowledge and awareness of 
cervical cancer were significant predictors of readiness 
to accept HPV vaccines17. A cross-sectional questionnaire 
survey has shown that women in Hong Kong are most 
concerned about the efficacy of the vaccine, duration 
of protection and long term side effects. The degree of 
concern is proportional to educational level18.  
Public health implication
Both the quadrivalent vaccine and the bivalent 
vaccine were implemented in many countries e.g. 
UK19, Australia, New Zealand, Canada etc. as part of 
their regional or national immunisation programmes 
against cervical cancer since their licensing from the 
year 2006. An ecological study in Australia showed 
that the incidence of high grade cervical abnormalities 
(CIN2/3 or AIS) in girls aged 18 or younger was 
decreased from 0.8% to 0.42% (47.5% decrease) within 
3 years of launching the Quadrivalent HPV vaccination 
programme. However, further studies are needed 
to confirm whether this ecological observation is 
attributable to vaccination20. 
Human papillomavirus (HPV) types 6 and 11 cause up 
to 90% of cases of genital warts21,22 . The incidence of 
genital warts in Hong Kong was estimated to be 203.7 
per 100,000 person-years (292.2 and 124.9 per 100,000 
person-years for males and females respectively)23. 
Analysis of national sentinel surveillance data in 
Australia showed a 59% decline in the number of 
diagnoses of genital warts in young female residents 
(age 12-26 years) after introduction of the quadrivalent 
HPV vaccination programme. There was also a 39% 
decline in the proportion of heterosexual men (aged 12-
26) diagnosed with genital warts during the vaccine 
period24,  suggesting HPV vaccine may provide 
protective effects in heterosexual men through herd 
immunity. 
Conclusion
Both vaccines demonstrate a high efficacy against 
HPV-16/18 related high grade cervical intraepithelial 
neoplasia and adenocarcinoma in situ (AIS). Currently, 
HPV vaccination is not included in the Hong Kong 
Childhood Immunisation Programme. Local study 
data may help in policy implementation for control 
and prevention of cervical cancers and genital warts 
in Hong Kong. On the other hand, it should be noted 
that vaccination only protects against selected HPV 
types and pre-cancerous cervical lesions are usually 
asymptomatic, the role of regular cervical cancer 
screening cannot be replaced by vaccination.
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Introduction 
Cervical cancer is the seventh most common female 
cancer in Hong Kong.  According to the Hong Kong 
Cancer Registry, there were 453 new cases of cervical 
cancer, and caused 128 deaths in the year of 20091. 
Cervical cancer is one of the few cancers that can be 
prevented by regular screening  The natural history of 
cervical cancer is well understood.  In most cases, there 
is a premalignant condition, cervical intraepithelial 
neoplasia (CIN), which can persist for many years 
before becoming invasive.  The cervical smear, a simple 
and non-invasive screening test, can readily identify this 
pre-malignant condition, which can be easily treated 
before it becomes malignant. Therefore, the correct 
management of abnormal cervical smears is crucial 
in the prevention of cervical cancers, while avoiding 
unnecessary treatment with its potential physical and 
psychological morbidities.
Current Cervical screening programme 
in Hong Kong 
The target population for cervical smear screening 
includes all women who have never had sexual 
experience. Screening should start from the age of 25 
or the time of their first sexual exposure (whichever is 
later). Nevertheless, women with high-risk profiles may 
consider starting below the age of 25. The Department 
of Health in Hong Kong recommends annual smears 
for two consecutive years, and if both are normal, the 
woman should have cervical smears every three years. 
Screening may be discontinued after the age of 65 if they 
have normal smears for three consecutive smears. 
It should be noted that a cervical biopsy, rather than a 
cervical smear, should be taken if an obvious growth is 
noted on examination. 
Patients with abnormal cervical smears
Most laboratories in Hong Kong use The Bethesda 
System2. The cervical cytology abnormalities can be 
broadly divided into squamous cell or glandular cell 
abnormalities. The management of abnormal cervical 
smears depends on the likelihood of the patients having 
a high-grade lesion, which may progress to invasive 
carcinoma. 
Squamous cell abnormalities
The categories of squamous cell abnormalities are listed 
in Table 1.
Table 1: Categories of abnormal squamous cytology and its 
significance5, 11
Atypical squamous cells of 
undetermined significance 
(ASCUS)
CIN 2-3: 7-12%
Atypical squamous cells, cannot 
exclude HSIL (ASC-H)
CIN 2-3: 26-68%
Low-grade squamous intra-
epithelial lesion (LSIL)
CIN 2-3 or above: 12-17%
High-grade squamous intra-
epithelial lesion (HSIL)
CIN 2-3 or above: 53-97%    
Invasive cancer: 2%
Squamous cell carcinoma Invasive cancer: 55.7%
For women with a single smear showing ASCUS, the 
incidence of high grade CIN (i.e. CIN 2/3) is around 
11%3, with a very low incidence of invasive cancer of 
0.1-0.2%. 
Two management options are available:4
1) Reflex HPV Testing# for high-risk oncogenic HPV 
types. Refer to colposcopy if HPV test is positive.  
2) Repeat cytology in 6 months. Refer to colposcopy 
if the repeated smear is abnormal.
Reflex HPV testing is preferred as it eliminates the need 
for the woman to return to the clinic for a repeat smear, 
and it can reassure many women that they do not have 
a significant lesion. Reflex HPV testing is also a more 
cost-effective strategy in detecting high grade CIN when 
compared with a repeated cytology.5
For women with smears showing squamous cell 
abnormalities other than ASCUS, there is a significant 
proportion of them having high grade CIN or invasive 
cancers (Table 1), therefore, all of them should be 
referred to colposcopy and biopsy4.
Glandular cells abnormalities
The two most common sources for glandular cells 
on cervical  smears are the endocervix and the 
endometrium. Less commonly, atypical glandular cells 
can also be found in women with neoplasms of the 
fallopian tubes or the ovaries.
The 2001 Bethesda System classifies glandular 
cell abnormalities into 4 different categories, and 
pathologists will try to indicate whether the origin of 
the glandular cells is endocervical, or endometrial:
- Atypical glandular cells, NOS
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- Atypical glandular cells, favour neoplastic 
- Adenocarcinoma-in-situ
- Adenocarcinoma
AGC is associated with CIN and squamous cell 
carcinoma, adenocarcinoma-in-situ and adenocarcinoma 
of the cervix, endometrial hyperplasia and endometrial 
carcinoma. The incidence of significant pathology was 
significantly higher in women with smears showing 
AGC-favour neoplasia (68-74%), than those with AGC-
NOS (19-33%) 6,7. Therefore, all patients with AGC should 
be referred for endocervical sampling, colposcopy and 
biopsy. Endometrial sampling should also be performed 
for women older than 35 years old or if they are at 
risk of endometrial neoplasia (e.g. abnormal vaginal 
bleeding or conditions with chronic anovulation)5. One 
exception to this is for women with AGC-endometrial 
cells, endometrial sampling should be performed first, 
and to refer for colposcopy if the endometrial sampling 
is negative4,5. Because of the high incidence of significant 
pathology in women with AIS or AGC-favour neoplasia, 
a diagnostic cold knife cone should be performed if all 
the workup is negative. 
Colposcopy
A colposcope is a low-power binocular microscope that 
allows magnification of the lower female genital tract 
(Fig. 1). The aim of colposcopy is to identify the worst 
area for biopsy and to assess the extent of the lesion. 
The transformation zone is the area of the cervix where 
the columnar epithelium is replaced by metaplastic 
squamous epithelium, and almost all squamous lesions 
occur in this area. For a colposcopic examination to be 
satisfactory, the whole transformation zone has to be 
examined. It is also important to examine the vagina at 
the time of colposcopy. 
Figure 1: Colposcope 
Figure 2: High grade lesion (at 7 o’clock position) appears 
as an aceto-white and iodine-negative lesion (upper – 
aceto-white lesion; middle – aceto-white lesion with 
abnormal vessels (on higher power); lower – iodine-negative 
are corresponding to the aceto-white lesion)
The cervix is first examined under the colposcope for 
any abnormal vessel pattern, which is best visualized 
with the use of a green filter. Afterwards, 5% acetic 
acid, followed by Lugol’s iodine, are applied to the 
cervix. Typically, CIN appears as an aceto-white lesion, 
which is iodine negative. Higher grade lesions may be 
associated with abnormal vascular patterns. (Fig. 2) For 
glandular lesions, there are no reliable, widely accepted 
colposcopic features. Moreover, most AIS occur in 
the endocervical canal, which makes colposcopic 
examination even more difficult.
Special population
Pregnant women
The incidence of abnormal cervical cytology in pregnant 
women is around 5% and is similar to the non-pregnant 
population. Studies have shown that a large proportion 
of cervical dysplasia regressed during pregnancy 
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(53-64%)8 and the progression rate from high-grade 
lesions to invasive cancer is extremely low (0-0.4%)9. 
Colposcopy is more difficult in pregnant women 
because of the changes in the cervix associated with 
pregnancy, and hence it should be performed by an 
experienced colposcopist. The main aim of colposcopy 
during pregnancy is to exclude invasive disease.
For pregnant women with ASCUS / LSIL on smears, 
it is reasonable to defer colposcopy until 6 weeks after 
delivery because of the low risk of malignancy and high 
rate of spontaneous regression4,5.
For pregnant women with smears showing HSIL / AGC, 
they should be referred for colposcopy as non-pregnant 
women to exclude invasive diseases. Repeat Colposcopy 
at the early third trimester may be considered4,5. 
Although cervical biopsy has been shown to be safe 
during pregnancy in the evaluation of abnormal smears, 
there are concerns about the risks of excessive bleeding 
because of the hypervascular cervix. Therefore, cervical 
biopsy is recommended only if a malignant lesion is 
suspected during colposcopy4. 
Adolescents (20 years or less)
Adolescents have a very low risk of cervical cancer. In 
Hong Kong, there were only 4 cases of cervical cancer 
diagnosed in girls younger than 20 years old for the 
period of 1999-20091.
The prevalence of HPV infection is high in adolescent 
women. Up to 80% of sexually active young women 
will be HPV DNA positive at some point after initiating 
sexual activities10. However, most of the HPV infections 
clear spontaneously after 2 years. Therefore, immediate 
referral for colposcopy is discouraged in adolescents 
unless the cervical smear shows HSIL4,5, because of 
the potential harm from over-investigation and over-
treatment. Instead, they should have a follow-up smear 
every 12 months4.
Adolescents who have a HSIL smear or persistent 
abnormal cervical cytology for 2 years should be 
referred for colposcopy4. 
Conclusion
Cervical cancer is a largely preventable disease. The 
correct management of abnormal cervical smears is an 
important element in the prevention of this potentially 
lethal condition. Clinicians should be familiar with 
the indications for referral for further investigations 
(e.g. colposcopy) for an abnormal smear, so that high-
grade pre-invasive conditions can be identified and 
managed accordingly before they progress to truly 
invasive disease, while avoiding over-investigation 
and over-treatment in  the women causing unnecessary 
psychological and physical morbidities. 
# Reflex HPV Testing - Testing either the original liquid-
based cytology residual specimen or a separate sample 
co-collected at the time of the initial screening visit for 
HPV testing.
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Introduction
Advances in medicine have made cancer survivors going 
back to community sooner and longer than what we 
had expected in the old days. Women are now delaying 
their child bearing and fertility conserving treatment for 
gynaecological cancers are being increasingly requested.
Cervical cancer is the second most common cancer 
in women aged between 15 and 44 worldwide1 and 
in Hong Kong, it is the fourth most common cancer 
in women aged between 20 and 442. Therefore, it is 
a nightmare to women, not only because of its high 
mortality rates, around 30% of all cases2, but also 
because of the loss of fertility after treatment.  Recently, 
if the disease can be diagnosed at an early stage, fertility 
conserving treatment can result with similar survival 
rates3-5 and an acceptable reproductive outcome6-9.
Problems in Hong Kong, data extracted 
from the Cancer Registry in Hong 
Kong, Hospital Authority2
With the help of colleagues who actively advise 
or perform cervical smear screening for our local 
population, we are seeing a steady decline in the 
incidence of the disease.  
Table 2. 2009 FIGO staging for Cervical Cancer10 
This is a clinical staging as most of the cases are to be 
treated by primary radiotherapy or chemo-irradiation. 
Stage 0 has been deleted from the staging as these cases 
should not be treated as cervical cancer. 
Treatment
Treatment of cervical cancer depends on the stage of the 
disease, risk factors of the disease and the fertility wish 
of the patient.
Primary surgery can be performed for surgically fit 
cases up to stage IIa1, non- bulky disease (tumour size 
< or = 4cm). For stage IA1 disease, they can be treated 
by conisation of the cervix or simple hysterectomy as 
the chance of metastasis or lymph nodes involvement 
is almost negligible. For stage IA2, IB1 and IIa1 disease, 
they will be offered a radical hysterectomy and pelvic 
lymphadenectomy. If she wishes to preserve her fertility 
and the tumour is smaller than 2cm without lymph 
node involvement, a radical trachelectomy and pelvic 
lymphadenectomy can be considered.
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However, if the patient is not surgically fit, primary 
radiotherapy can be offered with similar survival rates. 
Primary Chemo-irradiation should be offered for stage 
IIB or bulky disease (tumour size > 4cm) in women 
who are medically fit for chemotherapy. The dosage of 
chemotherapy is lower than normal treatment and it is 
used as a radio-sensitising agent to improve the survival 
outcomes when compared to primary radiotherapy 
alone11-15. 
Fertility conserving treatment
Professor Daniel  Dargent,  a pioneer of radical 
trachelectomy in treatment of early stage cervical 
cancers, had published his early works in 19943. Since 
then, there are more than 1000 reported cases of 
radical trachelectomy with similar survival rates when 
compared to radical hysterectomy for the same stage. 
The pregnancy rate is around 30% with half of those 
results in take home babies16. 
The laparoscopic route has replaced most of the 
abdominal route treatment in view of the better 
morbidity profile but similar surgical and survival 
outcomes17-19. A robotic route has now been used to 
adjuvant the laparoscopic route with comparable 
outcomes to abdominal and laparoscopic routes20-21. It 
was found that the robotic route results in a significantly 
lower morbidity profile than the laparoscopic route 
including lower conversion rates (conversion to 
laparotomy during operation), lower blood transfusion 
rates, less vaginal cuff dehiscence rates and shorter 
hospital stay22-24. Therefore, it is a better option for 
treatment of such oncological patients.
Robotic assisted laparoscopic radical hysterectomy has 
shown to have comparable outcomes to abdominal or 
laparoscopic radical hysterectomy25-26. The learning 
curve for a robotic assisted laparoscopic hysterectomy 
is found to be significantly shorter than conventional 
laparoscopic hysterectomy with shorter operative times 
and lower morbidity such as blood loss and hospital 
stay27-28.  
The technical aspect of a radical trachelectomy is 
much more complicated than a radical hysterectomy 
and the functional outcome is much more important 
than a radical hysterectomy, therefore the benefit of a 
robotic route can be estimated to be more in a radical 
trachelectomy than a radical hysterectomy16. Using the 
robotic system, the surgeons have better ergonomics, 
dexterity and angles of movement to perform selective 
resection and fine and complex suturing procedures in 
a narrow pelvis. The Hospital Authority will subsidise 
the use of the da Vinci Surgical System to assist in this 
procedure.
Treatment for recurrence
Last but not least, after primary treatment, one third 
still recurs. Only one third of those will be centrally 
located local pelvic recurrence that is suitable for a total 
exenteration with a 6-10% operative related mortality 
and 20-40% 5 years survival29-32.
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Background
Laboratory testing is a crucial element in the prevention 
of cervical cancers, by identification of cervical cancer 
cells or their pre-invasive lesions in cervical cytology 
and detection of the human papillomavirus (HPV), 
the necessary causative factor. Early identification of 
women at risk enables efficient treatment and enhances 
survival.
Cervical cancer screening is probably the most durable 
and effective cancer screening programme in medical 
history. The cervical cytology test, or the “Pap” test, 
refers to the collection of cells from the cervix (Figure 1), 
and transfer to a glass slide for detection of cancer and 
precursor cells. This principle has remained unchanged 
since its launch eight decades ago. In nearly all countries 
with good screening indexes, a remarkable reduction in 
the incidence of cervical cancers is achieved. Cervical 
cytology screening accounts for up to 80% reduction 
in mortality due to cervical cancer (Sasieni et al., 2009). 
The sensitivity and specificity of conventional cervical 
cytology for detecting CIN 2 to 3 is estimated to be 44-
80% and 91-96%, respectively (Rodriguez et al., 2010).
Figure 1. The uterine cervix is relatively accessible to periodic 
collections of cells for cancer screening.
Among cervical cancers, the incidence of squamous 
cell carcinomas is particularly reduced by screening 
a l though the  e f fec t  on  adenocarc inomas  and 
adenosquamous carcinomas is less obvious (Smith et 
al., 2000). This may be due to the deeper location of the 
latter two cancers in the endocervix and their detection 
is less effective. Cervical smears can occasionally detect 
cancers of the uterine corpus, ovaries or even extra-
genital organs (Tam et al., 2003; Wang et al., 2002). 
However, cervical cytology should not be considered as 
a screening tool for these malignancies.
Enhancement of cervical cancer 
screening
Infrastructure of cervical cytology screening: Cervical 
cytology is a good screening test but a single negative 
smear cannot exclude cancer (Castle et al., 2009). Both 
health care providers and patients need to understand 
the fact that successful cervical cancer screening relies 
on repeated cervical cytology testing and this should 
be done at suitable intervals. To ensure the success of 
cervical cytology screening, it is necessary to have a 
well-organised screening programme of good coverage, 
an adequate number of qualified cyto-technicians and 
pathologists, and matching resources for management 
with emphasis on quality assurance. 
Evolution of cervical cytology reporting system: A 
cervical cytology reporting system has evolved since its 
introduction due to the identification of the link between 
HPV and cervical cancers as well as the merging of 
dysplasia and carcinoma-in-situ into a spectrum CIN 
(Figure 2) (Nucci and Crum, 2007) The most widely 
practised cervical cytology reporting system is The 
Bethesda System (TBS). It was initially introduced by 
the National Cancer Institute (NCI) of USA in 1989 
(Solomon et al., 2002; Workshop, 1989) in which a binary 
classification of SIL in cytological reporting was adopted. 
Low-grade SIL (LSIL) includes abnormal cells from HPV 
infection and CIN I (Figure 3) whilst high-grade SIL 
(HSIL) refers to abnormal cells from CIN 2 and CIN 3 
(Figure 4) (Table 1). A more significant modification was 
further made in 2001 incorporating the increasing use 
of new processing methods, ancillary techniques and 
automated screening devices (Solomon et al., 2002). The 
unified terminology enables accurate communication 
between cyto-pathologists and gynaecologists, and 
between cervical cytology laboratories. Quality of 
samples and education notes on clinical follow-ups 
should also be included, with reference to consensus 
management guidelines prepared by local authorities. In 
Hong Kong, corresponding management guidelines were 
produced by the Hong Kong College of Obstetricians and 
Gynaecologists in 2002 and 2008 (Ngan et al., 2008).
Development of new laboratory techniques: To improve 
the sensitivity and specificity of cervical cancer screening, 
there is a blooming of techniques (Figure 5) (1) to improve 
the quality of the sample by liquid-based cytology; (2) to 
increase the efficiency of screening for abnormal cells by 
automated screening platform; (3) to detect risk factors 
particularly human papilloma virus (HPV) and (4) to 
provide predictive molecular markers.
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Figure 2. The spectrum of cervical intraepithelial neoplasia and 
squamous cell cancer.
Figure 3. Koilocytes with perinuclear halo and atypical nuclei are 
considered a diagnostic feature of HPV infection in cervical smear 
or biopsy.
Figure 4. High-grade SIL (HSIL) and squamous cell carcinoma cells 
found in a screening cervical smear.
Figure 5. New technologies including liquid- based cytology, 
computer assisted screening and molecular markers are increasingly 
applied to cervical cancer detections.
Table 1. A concise version of The 2001 Bethesda System (Solomon et 
al., 2002)
Squamous adequacy
• Satisfactory for evaluation 
• Unsatisfactory for evaluation
- Specimen rejected/not processed (specify reason)
- Specimen processed and examined, but unsatisfactory for 
evaluation of epithelial abnormality because of (specify 
reason)
General Categorisation
• Negative for intraepithelial lesion or malignancy
• Epithelial cell abnormality
• Other
Interpretation/Result
• Negative for Intraepithelial Lesion or Malignancy
- Organisms
- Other non-neoplastic findings, e.g. inflammation, radiation, 
intrauterine contraceptive device   
- Glandular cells status post-hysterectomy 
- Atrophy
Epithelial Cell Abnormalities
• Squamous cell
- Atypical squamous cells (ASC)
 of undetermined significance (ASC-US)
 cannot exclude HSIL (ASC-H)
-
-
-
Low-grade squamous intraepithelial lesion (LSIL), 
including HPV cytopathic effect and CIN 1
High-grade squamous intraepithelial lesion (HSIL), 
including CIN 2 and 3
Squamous cell carcinoma
• Glandular cell
- Atypical glandular cells (AGC) (specify endocervical, 
endometrial, or not otherwise specified)
- Atypical glandular cells, favor neoplastic (specify endocervical 
or not otherwise specified)   
- Endocervical adenocarcinoma in situ (AIS)
- Adenocarcinoma
• Other
Endometrial cells in a woman  40 years of age
Automated review and ancillary testing
Educational notes and suggestions
New laboratory techniques
Liquid-based cytology
Sampling or preparation errors have been shown 
to significantly affect the accuracy of cytology 
reporting (Gay et al., 1985; Linder and Zahniser, 1998). 
Conventional smears are traditionally taken with a 
wooden spatula, and the collected cellular material 
being smeared directly onto glass slides. The remaining 
collected cells were discarded together with the spatula 
but it has been reported that only 6.5% to 62.5% of the 
epithelial cells collected on the sampling spatula are 
deposited on the glass slide. Such sampling errors are 
responsible for a significant portion of false negative 
cervical cytology tests (Hutchinson et al., 1994). 
The development of liquid-based cytology system 
represents an important milestone in the practice 
of gynaecology and laboratory medicine. Liquid-
based cytology was initially developed in the 1990s 
as a preparation exclusively for use with automated 
screening devices. Ever since its introduction, however, 
it has performed so well in clinical trials against the 
conventional Pap smear, and it is now marketed 
independently to automated screening. 
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with a cervix brush, are fixed in a methanol-based 
preservative (PreservCyt) and subsequently processed 
in a manufacturer-specified instrument (ThinPrep 2000 
or ThinPrep 3000). Newer models are capable of batch 
processing. Using a filtering mechanism, the cells are 
vacuumed from the container against a filter, and then 
transferred onto a glass slide, followed by staining. The 
cells are spread over a circular area 20 mm in diameter in 
an almost monolayer sheet. 
Becton Dickinson Diagnostic currently owns the BD 
SurePath Pap test system, which is a merged company 
between the former AutoCyte Prep and CytoRich in the 
late 1990s. The specimen collection method is identical 
to ThinPrep but the cellular samples are fixed in an 
ethanol-based fixative (CytoRich) supplied by the 
manufacturer. The specimens are then processed by the 
manufacturer-supplied system, the BD PrepStain slide 
processor, which is a fully automated system capable 
of batch processing. The samples are centrifuged in a 
density reagent and then converted into an enriched cell 
pellet before deposition of the cellular material onto a 
glass slide over a circular area 13 mm in diameter.
The MonoPrep Pap test is the most recent liquid-based 
system approved by FDA for cervical cancer screening. 
The collection method is similar to other liquid-
based systems, but special collection instruments, the 
endocervical cytobrush and plastic cytospatula, are 
used. The transport medium is a buffered alcohol-based 
solution. The specimens are processed in a manufacturer-
supplied, fully automated MonoPrep Processor capable 
of batch processing. The slide preparation is very similar 
to the ThinPrep system that involves the use of a filtering 
mechanism. 
Although there is an overall improvement of quality 
with liquid-based preparations, they each have their 
inherent problematic issues, such as those related to 
specimens that are rich in mucus or blood. Each system 
has its own way of reducing this artifact.
Liquid-based cytology was found to be significantly 
more effective for the detection of LSIL and more severe 
lesions in several populations when compared with 
conventional smears, including our earlier study(Cheung 
et al., 2003; Gutman, 2000; Laverty et al., 1995; Lee et al., 
1997; McGoogan and Reith, 1996; Wilbur et al., 1994). 
Liquid-based cytology has also been reported to increase 
the sensitivity of detecting adenocarcinomas of the cervix 
(Schorge et al., 2002) and micro-organisms (Cheung et 
al., 2003).
The almost monolayer property of the liquid-based 
system preparations ensures their successful use with 
automated screening devices, such as the ThinPrep 
Imaging System and the BD FocalPoint Slide Profiler 
for ThinPrep and SurePath, respectively. Apart from 
their superior quality to the conventional Pap smear 
at a microscopic level, the liquid-based system has the 
added advantage of being able to produce additional 
preparations for use in educational or quality assurance 
programmes. The residual cellular samples may also be 
used for additional laboratory tests.
The residual exfoliated cells in liquid-based cytology also 
facilitates application of ancillary techniques for cervical 
Liquid-based cytology involves direct rinsing of 
cells from the collecting device in the fixation/
transport medium from which thin layer smears are 
produced. This approach increases the number of cells 
subsequently deposited on the glass slides (Figure 6), 
eliminates air-drying artifacts and removes obscuring 
factors due to abundant blood and inflammatory cells in 
the sample or thick cell smears in conventional smears 
(Figure 7). Therefore, reduction of the unsatisfactory 
rate is usually achieved, particularly in populations with 
high rates of unsatisfactory smears, for example due to 
high incidence of genital infections. 
Figure 6. Cervical epithelial cells are being collected by a broom 
device and then rinsed in a vial of fixative transport medium. Thin 
layer smears with a clear background are produced for microscopic 
evaluation.
Figure 7. A conventional smear (A) with abundant polymorphs and 
a liquid- based cytology smear (B) with a clean background.
Globally, the two most widely used liquid-based 
cytology devices include the ThinPrep and the BD 
SurePrep which were approved by the United States 
Food and Drugs Administration (FDA) for cervical 
cancer screening in 1996 and 1999, respectively (Cibas, 
2009). In Hong Kong, liquid-based cytology is now 
extensively used and contributes to around 70% of 
cervical cytology evaluation (Tay et al., 2008). There 
are several other liquid-based preparations currently 
available in the market but the majority is yet to be 
approved by FDA for cervical cancer screening. 
In 1996, ThinPrep (Hologic, Marlborough, MA, 
previously Cytyc Corporation) was the first liquid-based 
system approved by the Food and Drug Administration 
(FDA) for cervical cancer screening. Instead of spreading 
directly onto a glass slide as in the conventional 
Pap smear, the cellular samples, usually collected 
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cancer screening (Figure 5) (Cheung, 2007; Cheung et al., 
2003; Cheung et al., 2004b; Cheung et al., 2010; Keyhani-
Rofagha and Vesey-Shecket, 2002), such as detection 
of HPV, chlamydia, and gonorrhoea. Such approach 
is accepted for providing reflex HPV tests for women 
whose Pap tests are found to harbour atypical squamous 
cells of undetermined significance (ASC-US) (Ngan et 
al., 2008; Solomon et al., 2001; Wright et al., 2007)
Automated screening of cervical cytology
Cervical cytology evaluation is probably the only big 
volume medical test that has not been automated. 
There is high motivation to develop computer assisted 
evaluation of cervical smears (Baldwin et al., 2003; 
Wilbur, 2003). (1) The most important motivation is 
an attempt to reduce human errors. In a screening 
population, abnormal smears constitute a small portion 
(≈6%) of smears evaluated. Moreover, cyto-technicians 
need to evaluate more than 30,000 cells in one smear 
(Lozano, 2007) without knowing which smears harbour 
abnormal cells nor the nature of the abnormal cells. This 
combination of screening and interpretation procedures 
can be compared to the challenge of searching needles 
in haystacks (Figure 8). (2) Then there is the drive to 
reduce the manpower required for screening. The 
imager assisted screening is particularly helpful in 
handling the labour intensive and tiring screening 
process so that effort can be focused on interpreting the 
abnormal cells selected by the imager. 
Figure 8. Needle in a haystack.
As noted earlier, the currently popular liquid-based 
cytology preparations were initially developed as 
a by-product of automated screening devices. It is 
understandable that automated screening only works 
well on smears with clear background and little cell 
overlap. 
The PAPNET system is  the f irst  generation of 
commercialised automated smear screening system. The 
system scans the slides and identifies 128 most suspicious 
fields for the cyto-technicians or pathologists to check on 
a television monitor. 
The AutoPap /FocalPoint™ slide profiler, after scanning 
the smears on glass slides, ranks them according to 
potential abnormalities. It allows a certain portion (25%) 
of smears to be archived without review (Brown and 
Garber, 1999). It has been approved by FDA to be used as 
a primary cervical cytology screening tool. 
Using the ThinPrep Imaging System, the cells stained 
by DNA sensitive dyes are automatically screened. In 
every smear, 22 Fields of View (FOV) considered most 
worrying are identified and their x-y axis recorded. These 
22 FOV are then recalled using the Review Scope and 
evaluated by cyto-technicians (Figure 9). If no abnormal 
cells are found in these 22 FOV, the smear can be reported 
as negative after the quality control procedures have been 
followed. Otherwise, the whole smear will need to be 
manually checked for abnormal cells. 
Figure 9. Computer assisted screening. (A) The ThinPrepR Imaging 
System is composed of the Image Processor, computer and 
automated Review Scopes. (B) Liquid- based cytology slides bear 
fiducial marks for location of the field of view. (C) An aggregate of 
HSIL cells identified by the imager in an electronically marked field 
of view. 
Irrespective of the type of imager being used, cases 
with abnormal cells found and cases with significant 
clinical concern have to be referred to cyto-pathologists 
for evaluation and reporting. All negative cases should 
undergone quality control rescreening before reports are 
issued.
Detection of HSIL/LSIL
In most studies, a significant increase in detection 
of HSIL or above lesions can be found after the use 
of imager assisted screening (Biscotti et al., 2005; 
Chivukula et al., 2007; Davey et al., 2007; Dziura et al., 
2006; Lozano, 2007; Miller et al., 2007). In fact, a very 
low detection rate of high risk HPV DNA (1.9% to 3.9%) 
was found in women whose liquid-based cytology 
smears were reported to be negative by imager assisted 
screening (Bansal et al., 2009; Cibas et al., 2007; Zhao 
et al., 2007). These findings support the high negative 
predictive value of image assisted screening for HPV 
related cytological changes. 
HPV tests
There has been a remarkable advancement in the 
molecular detection and genotyping of HPV in recent 
years (Cheung, 2007; Cuschieri et al., 2005). HPV DNA 
testing with HC2 can be performed in the liquid-based 
cervical cytology cellular residues or direct samples 
(Sherman et al., 1997). HPV tests have been increasingly 
used for triage of borderline smears of ASC-US, primary 
screening and as a test of cure. However, clinicians 
and health care professionals need to understand the 
advantages and limitations of different HPV tests for the 
benefit of our women (Table 2). 
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Table 2. Summary of HPV molecular testing
HPV test Manufacturer HPV 
Detection
HPV 
Genotyping
Identify 
Multiple 
Infections in 
1 test
Hybrid 
Capture 2
Qiagen 13 HR HPV NA NA
Amplicor Roche 13 HR HPV NA NA
Cervista Hologic 14 HR HPV HPV16/18 NA
Cobas HPV Roche 14 HR HPV HPV16/18 NA
Realtime HR 
HPV 
Abbott 14 HR HPV HPV16/18 NA
Aptima HPV GenProbe 14 HR HPV NA NA
Linear Array Roche Multiple 
HPV
Yes Yes
HPV Chips Various Multiple 
HPV
Yes Yes
PCR- 
Sequencing
- Yes Yes NA
NA  Not available
Different types of HPV tests
Historically, HPV infection was first identified by 
morphological identification of koilocytes (Figure 3) 
in either cytology or tissue biopsy samples. Electron 
microscopy, immunohistochemistry and various 
molecular biology methods were subsequently 
employed (Cheung, 2007) (Figure 10). 
Figure 10. Commonly used HPV detection tests.
For HPV In situ hybridisation (ISH), complementary 
DNA or RNA labelled probes are applied directly onto 
tissue sections or cytology smears (Bewtra et al., 2005; 
Kong et al., 2007). The Ventana Inform HPV assay, for 
example, is a commercially available chromogenic ISH 
test that has been reported to enhance the sensitivity of 
HSIL (Davis-Devine et al., 2005; Guo et al., 2008). 
PCR and/or Sequencing: DNA can be extracted from 
a direct cervical swab sample, liquid-based cytology 
residue, archival cervical smears, formalin-fixed 
paraffin-embedded or frozen tissue samples (Tabrizi et 
al., 2010). Amplification of the DNA template by PCR 
with general or consensus primers, such as GP5/6 and 
modified GP5+/6+, MY09/11 or modified PGMY09/11, 
and SPF primer set, targeting the L1 region of HPV, are 
commonly applied for the detection of HPV (Liu et al., 
2008; Ngan et al., 2002). PCR products of different sizes 
due to different HPV types are amplified. Comparison 
of the HPV DNA sequence in the sample with sequences 
of known HPV genotypes enables identification of the 
HPV genotype (Figure 11) (Liu et al., 2008; Ngan et al., 
1999a; Ngan et al., 1999b; Ngan et al., 1999c). However, 
PCR and/or Sanger sequencing are labour intensive and 
may not be suitable for high throughput processing. 
Moreover, it cannot detect multiple HPV infections 
in a sample. Nevertheless, PCR and/or sequencing is 
considered a good quality control tool.
Figure 11. DNA sequencing from a cervical cytology sample matched 
that of HPV 16.
The Hybrid Capture assays (HC2) is currently still the 
most widely adopted HPV test. It is the first HPV test 
that was approved by FDA and can identify 13 high-
risk HPV types (Figure 12) or 5 low risk HPV types. This 
chemiluminescent-based signal amplified assay has been 
reported to perform at a level of sensitivity comparable 
to that of polymerase chain reaction (PCR) (Peyton et al., 
1998) with less problems of contamination. 
Figure 12 Hybrid capture 2 print out showing status of samples 
with 13 HR HPV with positive and negative controls. 
To enhance the specificity for cervical cancer detection, 
inclusion of HPV16 and 18 genotyping is incorporated 
in various techniques (Cuzick et al., 2010; Stoler et al., 
2011; Wong et al., 2011). This is because HPV16 and 
HPV18 have been identified in about 50% and 20% of 
cervical cancers and high grade CIN/SIL, respectively 
(Chan et al., 2009a; Chan et al., 2009b; de Sanjose et al., 
2007; IARC, 2007; Liu et al., 2008; zur Hausen, 1994). 
The Cervista™ HPV HR Test is another signal amplified 
technology that was approved by FDA (Day et al., 
2009). Besides detecting 14 HPV high risk types, it 
can also detect the presence or absence of HPV 16/18. 
It is claimed to achieve high sensitivity and negative 
predictive value (NPV) in detecting CIN3+ or above as 
well as absence of cross-reactivity with common low 
risk HPV types (Kinney et al., 2010).
Similarly, the Abbott RealTime High Risk HPV is a 
qualitative in vitro PCR assay ?that 14 high risk HPV 
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genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 
68)? and can partially genotype HPV 16 and 18 from 
other 12 high risk genotypes (Wong et al., 2011). 
The Roche cobas® 4800 HPV Test is an automated, 
PCR-based, qualitative multiplex assay which has been 
recently approved by FDA. It provides genotyping 
information for HPV 16 and 18 besides detecting the 
presence of 12 other HR-HPV types (31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66 and 68) at clinically relevant infection 
levels (Figure 13) (Stoler et al., 2011). 
Figure 13. Cobas 4800 HPV test print out showing HPV status of 
samples with 13 HR HPV +/- 16/18.
HPV genotyping: The Roche linear array incorporates 
PGMY09/11 PCR with a line blot assay and detects 37 
HPV genotypes (Figure 14) (Stevens et al., 2007; Stevens 
et al., 2006). It is widely used as a validation assay for 
various HPV genotyping kits (Wong et al., 2012). It can 
identify multiple HPV infections and is often used in 
epidemiological studies. 
Figure 14. Roche linear array strips showing presence of multiple 
infections of HPV 39, 59 and 45. The former two are high risk HPV.
HPV DNA chips constructed from consensus PCR 
products of L1 and E6/E7 gene sequences of HPV are 
reported to be reliable for the detection and genotyping 
of HPV as a high-throughput screening test. Locally 
developed HPV DNA arrays such as SNIPER® HPV 
Genotyping Biochip Assay (Yip et al., 2010); GenoArray 
human papillomavirus (HPV) genotyping assay (Liu et 
al., 2010) and GenoFlow human papillomavirus (HPV) 
test (Wong et al., 2012) (Figure 15) are reported to 
demonstrate sensitivity and specificity similar to that of 
the Roche Linear Array HPV genotyping assay .
Figure 15. Three Genoflow HPV chips showing presence of HPV 16, 
HPV 58 and absence of HPV (from left to right).
While the above tests evaluate the existence of HPV 
DNA, detection of HPV RNA is also important. Active 
HPV infection can be detected by RNA transcription 
of specific HPV genes using RT-PCR or real time PCR. 
Commercially available E6/E7 mRNA assays such as the 
Pretect® HPV Proofer (NorChip) for 5 HR HPV types 
and APTIMA (Gen-Probe) for 14 HR HPV types have 
been found to be more specific for the detection of CIN3 
when compared with DNA genotyping (Ratnam et al., 
2010; Ratnam et al., 2011). RNA transcript detection at 
a single time point has also been reported to identify 
persistent infections without the need for repeated 
testing (Cuschieri and Wentzensen, 2008).
Impact of psychosocial factors
Health care professionals should be aware of the 
potential psychosocial impact of abnormal cervical 
cytology or HPV test results (Gath et al., 1995; Kwan et 
al., 2011; Kwan et al., 2012; Pirotta et al., 2009). Besides 
the fear for cancer, women found to be positive for 
HPV or diagnosed to have HPV related diseases may 
experience guilt and anger due to the stigmata of HPV 
infection as a sexually transmitted infection. Local 
studies in Hong Kong have shown that our women 
community has limited knowledge on cervical cancer or 
HPV and its related diseases (Kwan et al., 2009; Kwan 
et al., 2008; Lee et al., 2007). On the other hand, most 
women trust their doctors or health service providers for 
HPV related information (Pitts et al., 2007). Therefore, 
we should be active in learning about HPV and educate 
the public on the issue. 
Molecular markers for cervical cancer detection
The most common abnormal cytological finding 
encountered in a screening programme is ASC-US. 
ASC-US is diagnosed in about 3-4% of screening 
smears (Cheung et al., 2003) and is associated with a 
significantly higher chance of harbouring cervical cancer 
and HSIL (Cheung et al., 2004b). HPV DNA testing is 
an option in the triage of women with ASC-US. If the 
ASC-US samples are positive for HPV, the women can 
be referred for colposcopy directly while women who 
are HPV negative can be reassured (Ngan et al., 2008). 
This practice allows early referrals for colposcopy and 
earlier diagnosis of HSIL or even cancer and relieve 
the anxiety of those women while they wait for their 
repeat cytology tests (Maissi et al., 2004). High risk HPV 
DNA testing has also been suggested to be a test for 
primary screening and as a test of cure in communities 
with enough resources. However, high risk HPV can be 
found in 8% of our local population and 50% of ASC-US 
cases (Heider et al., 2011; Liu et al., 2008). To improve 
specificity of identifying women who harbour cancer 
precursors, additional markers are being explored to 
distinguish cancer or dysplastic cells from reactive cells 
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and to predict whether a CIN will progress or regress. 
ProExC and p16INK4a were widely studied. 
ProEx C (BD Tripath) is a cocktail immunocytochemical 
test that evaluates the expression of topoisomerase II-A 
and minichromosome maintenance protein 2 (MCM2) 
which are associated with host DNA integrity and cell 
cycle regulation  (Kelly et al., 2006). It can be used in 
cytology and surgical pathology specimens.
p16INK4a is a cyclin-dependent kinase inhibitor. 
Upon HPV infection, Rb is inactivated by E7 causing 
paradoxically raised levels of p16INK4a (Klaes et al., 2001; 
Wentzensen et al., 2005). Overexpression of p16INK4a 
was demonstrated in both CIN and cervical cancer 
and has become a surrogate marker of HPV infection. 
Immunocytochemistry for Ki-67, another marker for cell 
cycle progression, can be applied to liquid-based cervical 
cytology to enhance the detection of carcinoma cells and 
precursors (Cheung et al., 2004b) (Cheung et al., 2004a). 
p16INK4a and Ki67 co-expression (CINtec® PLUS ) are 
being explored for identifying dysplastic cells (Loghavi et 
al., 2012; Wentzensen et al., 2007).
Quality control in cervical cancer 
screening tests
Quality control is important for all tests including 
cytology, HPV tests and biomarker analysis. A modern 
cytology laboratory of high standard should have 
means to monitor its quality to ensure issued reports 
are accurate, reliable and informative and delivered in a 
timely manner. 
For cervical cytology evaluation, these include 
prospective rescreening of negative cases before issue of 
reports (random 10% negative or 100% rapid rescreen of 
all negative cases), retrospective review of all negative 
cytology in the past 5 years for a new case diagnosed with 
high-grade lesion or carcinoma, and cytologic-histologic 
correlation exercises. There should be a policy on how 
these different quality control exercises are carried 
out and stated in the standard operating procedure 
manual. False-negative cases should be documented, 
reviewed and recorded and followed by a revised report. 
The results of these quality control exercises can be 
used as performance indicators for cyto-technologists/
pathologists and for the laboratory.
Similarly, a molecular pathology laboratory reporting 
HPV tests must also have a written quality control 
programme for detection of errors. One need to bear in 
mind that false negative and positive results can occur 
in molecular pathology tests including HPV tests. For 
instance, false negative HPV test results can occur due to 
insufficient cellularity in the samples, L1 gene deletion, 
PCR competition and inhibition of the assays. All steps of 
the HPV tests from specimen collection (pre-analytical) 
to inclusion of proper controls (analytical) and proper 
issuing of patients’ reports (post-analytical) should be 
monitored. Both the molecular pathology laboratory and 
the referring physician should understand the limitations 
of the methodology being employed.
Laboratories with high standards are usually accredited 
by either one or the other local or overseas laboratory 
accreditation bodies. These include Tthe College of 
American Pathologists (CAP), National Association of 
Testing Authorities, Australia (NATA) and Hong Kong 
Laboratory Accreditation Scheme (HOKLAS). 
Future Perspective in the post HPV 
Vaccine era
Future cervical cancer screening is likely to be affected 
by the discovery and launching of the HPV vaccine 
(Schiffman, 2007). With the decreasing prevalence of 
HPV16 and HPV18 infections in the population, it is 
possible that serious cytology abnormalities, particularly 
HSIL and carcinoma, caused by these two vaccine 
covered genotypes will disappear. The remaining 
cytological abnormalities are likely to be of low grade 
or equivocal after vaccine is implemented. Moreover, 
obvious and reliable colposcopic abnormalities that are 
often caused by HPV16 will also be disappearing. Even 
for cocktail HPV tests such as HC2, the PPV will decrease, 
since the clinically significant cases due to HPV16/18 and 
related types will most likely be prevented by the vaccine.
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MEDICAL   DIARY
香 港 醫 訊
We have limited stock of the hard bound Medical 
Diary 2011 for sale.
For $150, you can keep a collection of all 12 
monthly issues of the Medical Diary for the year.   
4/F, Duke of Windsor Social Service Building, 
15 Hennessy Road, Wanchai, Hong Kong
Tel: (852) 2527 8898        Fax: (852) 2865 0345          
E-mail: info@fmshk.org  
Copy can be purchased in person during oce hour (9am 
to 6pm, Mon to Fri) by cash or cheque in $150.
Or copy to be sent out by courier by an additional charge 
of $30 for domestic courier service. Please send the reply 
slip with cheque in $180 made payable to 
"The Federation of Medical Societies of Hong Kong".  
 Name: ______________________________________
Tel. No.: _____________________________________       
Email Address: ________________________________
Corresponding Address: ________________________
____________________________________________
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Dermatological Quiz
Dr. Ka-ho LAU
MBBS(HK), FRCP(Edin, Glasg), FHKCP, FHKAM(Med)
Yaumatei Dermatology Clinic, Social Hygiene Service
Fig. 6: Ulcer on left lateral chest wall (close-up)
This 55 year-old man noticed a red painful lesion developed over his 
left lateral chest wall for a few weeks which rapidly increased in size 
and broke down into this large painful ulcer (Fig. 6) with purulent 
discharge.  He had history of Crohn’s disease followed up regularly by 
gastroenterologists.  He had seen various doctors and tried different 
topical treatments and oral antibiotics with no improvement.  Skin 
biopsy showed diffuse neutrophils at the base of the ulceration and 
non-specific tissue necrosis with surrounding mononuclear cell 
infiltrates at the ulcer edge.  Special stains and tissue culture for 
bacterial, mycobacterial, fungal and viral agents were all negative.  
Imaging:
1.  What is your clinical diagnosis or differential diagnoses?
2.  How will you manage this man?
(See P. 44 for answers)
Dr. Ka-ho LAU
Dermatological Quiz
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PRESS RELEASE        Oct. 18, 2012
THE FEDERATION OF MEDICIAL SOCIETIES OF HONG KONG
In response to the recent serious medical incident and related public discussion, the Federation of Medical Societies of Hong Kong would like to make the 
following announcements:
1. The monitoring of cosmetic business in relation to medical related procedures
In the best interests of consumers and patients, there must be a clear line drawn between cosmetic business and cosmetic medicine. Cosmetic business is 
commercial activity subject to consumer safety protection regulations. Cosmetic medicine involves many medical specialties. This is a form of medical 
treatment provided by doctors. Only registered medical practitioners or registered dentists are allowed to provide cosmetic treatments appropriate to their 
specialties, level of training and experience. For patient safety protection, any doctors with misconducts or providing services below the expected standards 
will be subjected to disciplinary actions by the regulatory professional bodies.
The following are some relevant suggestions regarding this aspect:
a. Define in detail what process or treatment should not be carried out by commercial business entities, including cosmetic business, in the 
absence of registered doctors.
b. Continuous and regular monitoring of cosmetic business.
c. More education to the public on potential risk and dangers related to cosmetic treatment, so that citizens can make a fully informed choice 
of their own.
d. Monitoring of advertisement in beauty business especially its genuineness.
2. The monitoring of use of experimental procedures, and blood and pharmaceutical Products
All clinical procedures of experimental nature, or of a high risk/benefit ratio, which are not yet evidence based or clinically proven, should only be 
performed with prior approval by appropriate ethical review board and written informed consent of the patients. The procedure needs to be supported 
with independent expert opinion, and carried out only by professionals with accredited training in the field. Procedures involving blood products and any 
pharmaceutical products should always be performed with the highest level of infection control, safety measures and other aspects of care in mind.
In line with other developed countries, the Hong Kong SAR Government should set up guidelines to regulate the use of human cellular products including 
the use of stem cells and ex-vivo expanded immune cells.
3. The doctors’ professional conduct
From the ancient days more than 2000 years ago in Greece with the Hippocratic Oath, to the modern days of Declaration of Geneva and code of good 
practice by various international professional bodies and medical councils, doctors have always been required to follow a very strict conduct.
Doctors should always put their patients’ health as the first consideration, to do them good and do no harm. Doctors should respect their patients and their 
privacy, and safeguard the professional dignity and professionalism. Doctors should not permit consideration of factors such as ethnic origin, nationality, 
political affiliation, social standing or any other factors to intervene between their duties and their patients. Such factors would also include financial 
advantages.
Doctors should always remind ourselves of these principles and code of conduct. Our patients place their health and lives in doctors’ hands, and doctors 
shoulder a huge responsibility. With an ever-evolving modern world of medicine and technology, medical professionals will continue to face ethical issues 
and moral challenges. It is of utmost importance that the medical professionals should abide by the well laid out professional conduct, and as the old 
Chinese saying goes, treat your patients like treating your own children.
The Federation of Medical Societies of Hong Kong was established in 1965, and currently has a membership of 131 professional societies. Founding 
members are Hong Kong Medical Association and British Medical Association (Hong Kong Branch). Member societies include doctors, dentists, nursing, 
pharmaceutical and allied health professionals. The Federation of Medical Societies of Hong Kong endeavours to provide the leadership and mechanism 
whereby the activities of member societies can be coordinated to promote professional interests, achieve fraternity and to advance common ideals of the 
medical and health professions of Hong Kong.
The press statement is issued by the Executive Committee of Federation of Medical Societies of Hong Kong and with support from the following member 
societies:
以上聲明由香港醫學組織聯會的執行委員會及下列各學會聯同發出：
1. Association for Integrative Aesthetic Medicine, Hong Kong 
Limited
香港中西醫美容醫學學會有限公司
2. Australian Doctors & Dentists Association of Hong Kong
香港澳州西醫及牙醫協會
3. British Medical Association (HK Branch)
4. College of Nursing, Hong Kong 
香港護理學會
5. Hong Kong Association for Integration of Chinese-Western 
Medicine 
香港中西醫結合學會
6. Hong Kong Association of Cosmetic Surgery Limited 
香港整容外科及醫學美容醫學會有限公司
7. Hong Kong Chinese Medical Association
香港中華醫學會
8. Hong Kong College of Emergency Medicine 
香港急症科醫學會
9. Hong Kong College of Health Service Executives 
香港醫務行政學院有限公司
10. Hong Kong College of Paediatricians 
香港兒科醫學院
11. Hong Kong Dental Association (Ltd.)
香港牙醫學會 ( 有限公司 )
12. Hong Kong Midwives Association 
香港助產士會
13. Hong Kong Paediatric Haematology & Oncology Study Group 
香港兒童血液及腫瘤科學會
14. Hong Kong Palliative Nursing Association 
香港紓緩護理學會
15. Hong Kong Psychogeriatric Association 
香港老年精神科學會
16. Hong Kong Society for Emergency Medicine and Surgery 
Limited 
香港急症醫學
17. Hong Kong Society for Histocompatibility and Immunogenetics 
Limited
香港組織相容性及免疫遺傳學學會有限公司
18. Hong Kong Society for Molecular Diagnostic Sciences Limited 
香港分子生物診斷學會有限公司
19. Hong Kong Society for Nursing Education 
香港護理教育學會
20. Hong Kong Society for the Study of Thalassaemia 
香港地中海貧血學會
21. Hong Kong Society of Biological Psychiatry
22. Hong Kong Society of Certified Prosthetist–Orthotists 
香港義肢矯形師學會
23. Hong Kong Society of Critical Care Medicine 
香港危重病學會
24. Hong Kong Society of Medical Genetics 
香港醫學遺傳學學會
25. Hong Kong Society of Minimal Access Surgery 
香港微創外科學會
26. Hong Kong Society of Plastic, Reconstructive and Aesthetic 
Surgeons
香港整形及整容外科醫學會
27. Hong Kong Surgical Laser Association 
香港鐳射醫學會
28. The College of Dental Surgeons of Hong Kong 
香港牙科醫學院
29. The Hong Kong Association for the Study of Liver Diseases 
Limited 
香港肝病學會
30. The Hong Kong Association of Oral and Maxillofacial 
Surgeons Ltd 
香港口腔頜面外科學會
31. The Hong Kong Cancer Therapy Society 
香港腫瘤化療學會
32. The Hong Kong College of Anaesthesiologists 
香港麻醉科醫學院
33. The Hong Kong College of Mental Health Nursing Limited 
香港精神健康護理學院
34. The Hong Kong Nutrition Association Limited 
香港營養學會有限公司
35. The Hong Kong Paediatric Society 
香港兒科醫學會
36. The Hong Kong Pain Society Limited 
香港疼痛學會有限公司
37. The Hong Kong Society for Infectious Diseases 
香港傳染病醫學會
38. The Hong Kong Society of Cytogenetics Limited 
香港細胞遺傳學學會有限公司
39. The Hong Kong Society of Diagnostic Radiologists 
香港放射診斷科醫生協會
40. The Hong Kong Society of Haematology 
香港血液科學會
41. The Hong Kong Society of Professional Optometrists 
香港眼科視光師學會
42. The Hong Kong Society of Rheumatology 
香港風濕學學會
43. The North American Medical Association Limited 
美加醫學會
44. The Pharmaceutical Distributors Association of Hong Kong 
Limited 
香港醫藥經銷業協會有限公司
45. The Society of Anaesthetists of Hong Kong 
香港麻醉科學會
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FMSHK Press Conference on Oct 18th
Central & Western Health Festival 2012/2013
Recent medical beauty treatment incidents have drawn public attention. In response to the serious nature and the 
related public and professional concerns, the Federation of Medical Societies of Hong Kong has collected member 
societies’ feedback and held a press conference on 18 October 2012, presenting a statement with suggestions 
and recommendations on this issue. The statement is supported as at to date by 45 member societies. (The Press 
Release is on Page 35) 
With support of the media, the summary was reported in television news and 14 local newspapers. We hope that 
the reflected opinion would help reinforce the professionalism amongst our medical and health colleagues, and 
serve as a useful reference for the government in planning and consulting for future measures and directions. 
The HKFMS Foundation Limited is delighted to continue the support and participation for the annual Central 
and Western Health Festival. This year, the Festival was successfully held on 3-4 November in the Sheung Wan 
Sports Centre. In the two-day Festival, over 2,400 citizens joined the Foundation activities, namely 3 health talks, 
occupational therapy game booths, dental checks and eye tests. We would like to express our sincere thanks 
to the following speakers and member societies, namely Dr. Priscilla WONG of the Hong Kong Society of 
Rheumatology, Dr. Siu-keung LAM of the Hong Kong Society for Colposcopy and Cervical Pathology, Dr. Tai-
nin CHAU of the Hong Kong Association for the Study of Liver Diseases; the Hong Kong Society of Professional 
Optometrists, the Hong Kong Occupational Therapy Association and Dr. Sai-kwing CHAN, Second Vice-
President of the Federation. We would also like to thank the following sponsors for their gifts and support: 
Abbott Medical Optics, Colgate, Culture Homes, Hong Wo Pharmaceutical, International Medical, Mekim, Oral-B 
and Skyview Optical. 
Federation News
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Six Sigma Seminar
Photo Exhibition of the Project of Photog-buddy
Photog-buddy is a project of personal development for a group of bereaved teenagers aged 13 to 19, co-organised 
by the HKFMS Foundation Limited and Togetherness. This is part of an ongoing charity project for bereaved 
children supported by the HKFMS Foundation. Through 8 weeks of learning photography techniques and 
joining outdoor practices, participants were emotionally guided to build a healthy personality and to reform their 
spiritual direction. The workshop, which consisted of eight 3-hour sessions (2pm to 5pm on Saturdays), has been 
successfully completed in July and August. Voluntary tutors taught photography techniques and self-expression 
skill as well as tips to define self-oriented themes on photography. Therefore, the bereaved teenagers could leave 
the past behind, cherish the present and look forward to the future.
The exhibition was held at the Gallery, HKICC Lee Shau Kee School of Creativity on 18-21 October, aimed 
at encouraging public awareness on caring those adolescents, thereby assisting them to overcome their 
psychological barriers. It was our honour to have various distinguished guests to officiate the celebration 
ceremony on 20 October. The participated teenagers were given much encouragement for their growth and 
positive changes, and guests were also touched by the appreciation and efforts from the bereaved children. 
Through the numerous creative artworks and the photographs displayed during the exhibition, the awareness 
of the public on the needs of the bereaved children was enhanced. The HKFMS Foundation looks forward to 
collaborate further with various partners to promote this worthy cause, in helping the bereaved youngsters to 
brave their adversity and become the future pillars of our society.
(From left to right: Mr. Dickie HUNG & Mr. Danny CHO, workshop tutors, Ms. Dorothy WONG, Representative of Hospice Care, 
Ms. Flori LAM, Council Member of Hong Kong Pain Society, Mr. Benjamin LEE, Hon. Treasurer of the Foundation, Dr. Raymond 
LO, President of the Foundation, Ms. Christina SUN, CEO of Togetherness, Dr. Chun-key LAW, President of Hong Kong College of 
Radiologists, Ms. Joyce CHENG, Hospital Ward Manager of the Sha Tin Hospital, Dr. Po-wan KO, Hon. Secretary of The Hong Kong 
Paediatric Society and Ms. Pearl TSE, Ex-CEO of Togetherness)
On 30th October the Federation co-organised a free seminar with the Six Sigma 
Institute for the member societies of our Federation. The speaker, Dr KC CHAN, 
shared the successful experiences of deploying Lean Six Sigma in Health Care 
and introduced the appropriate management tools for medical organisations. The 
seminar was successfully conducted with positive feedback from the audience, 
representing participation from 29 member societies. The Federation hopes the 
seminar could help disseminate the notion of customer focus in the workplace 
of medical industry, with the ultimate objective to enhance effectiveness and 
efficiency within limited resources. Feedback and suggestions to the FMSHK 
secretariat for organising further training courses on health management are 
welcome.
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New Members
HONG KONG SOCIETY OF PAEDIATRIC RESPIROLOGY
The Hong Kong Association for 
Child and Adolescent Psychology and Psychiatry
c/o Department of Paediatrics, Kwong Wah Hospital, 25 Waterloo Road, Yaumatei, Kowloon, HK.
Tel.: 3517 5055      Fax: 3517 5164    Home page: http://www.hkspr.org
The Hong Kong Society of Paediatric Respirology was founded in 
1997 with the mission of promoting the development of paediatric 
respirology and critical care. Under the leadership of our previous 
presidents Dr So Kwan-tong and Dr Alfred Tam and our current 
president Dr Daniel Ng, the Society has established our present 
leading position in Hong Kong and Asia. We hold regular clinical 
meetings and our annual scientific meetings are always well 
attended. We have developed guidelines on asthma, sleep disorders 
and recurrent wheeze in children. We have frequent exchanges 
with our sister societies in China Mainland and Taiwan. There are 
three main areas that we will be focusing on in the coming years, 
i.e. research, training, and accreditation. These are important in 
the future development of paediatric respirology as a recognizsed 
subspecialty in Hong Kong.
Chow Pok-yu
Honorary Secretary
The Hong Kong Association for Child and Adolescent Psychology and Psychiatry was founded in 1988. Membership 
of the Association spans across a wide range of professional fields such as child psychiatrists, child psychologists, 
child psychiatric nurses, occupational therapists and psychiatric social workers working with children and 
adolescents. It is also extended to any person, who by his / her profession, works for the mental health of children 
and adolescents as well as to any student who is currently undertaking training in courses related to child and 
adolescent mental health. 
The objectives of the Association are to (1) promote and advocate for better mental health of children and 
adolescents, (2) promote a better understanding of child and adolescent mental health among the public, (3) promote 
professional standards of all kinds of professionals working on the mental health of children and adolescents, and (4) 
cooperate with similar organisations in Hong Kong and other countries with a view to improve the mental health of 
children and adolescents. 
In the past few years, the Association had focused in organising scientific meetings/ conferences/ seminars on a 
variety of interesting topics. In future, we look forward to more collaboration opportunities with members of The 
Federation of Medical Societies of Hong Kong and other professional bodies.
Members of the executive committee:
Chairman Dr. S F Hung
Honorary Consultant, Kwai Chung Hospital
Vice-Chairman Professor Patrick W L Leung
Professor, Department of Psychology, Chinese 
University of Hong Kong
Hon. Secretary Dr. C P Tang
Consultant, Kwai Chung Hospital
Hon. Treasurer Dr. Y K Lee
Associate Consultant, Department of Psychiatry, 
United Christian Hospital
Committee 
Member
Professor Ernest S L Luk
Adjunct Professor, Department of Psychiatry, Chinese 
University of Hong Kong
Committee 
Member
Professor Kelly Y C Lai
Associate Professor, Department of Psychiatry, Chinese 
University of Hong Kong
Committee 
Member
Dr. T P Ho
Honorary Clinical Associate Professor, Department of 
Psychiatry, Hong Kong University
Committee 
Member
Dr. Phyllis K L Chan
Consultant, Department of Psychiatry, Queen Mary Hospital
Committee 
Member
Dr. C C Lee
Consultant, Kwai Chung Hospital
Committee 
Member
Dr. T S Lai
Private Psychiatrist
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SAT
Ms. Shirley MA
Tel: 2468 54021 19th Annual Scientific Meeting- Radiation Oncology in Neurosurgical PracticeOrganiser: Hong Kong Neurosurgical Society, Speaker: Dr. Reinhard E Wurm, Venue: Langham Hotel, 8 Peking Road, TST
Date  / Time Function Enquiry / Remarks
9:00 am
TUE
Ms. Wendy CHENG
Tel: 2824 0333
1 CME point4
HKMA Shatin Doctors Network - The Management Landscape of Atopic Dermatitis
Organiser: HKMA Shatin Doctors Network, Chairman: Dr. MAK Wing Kin, Speaker: Dr. 
LO Kuen Kong, Venue: Jasmine Room, Level 2, Royal Park Hotel, Shatin, Hong Kong
1:00 pm
THU
Mr. Alan LAW
Tel: 2527 82856
HKMA NTW Community Network-Latest Development in Modern Oral Contraceptives
Organiser: HKMA NTW Community Network, Chairman: Dr. WONG Yu Man, James, 
Speaker: Dr. KUN Ka Yan, Venue: Maxim's Palace, Tuen Mun
HKMA CME Dept.
Tel: 2527 8452
2 CME points 
HKMA CME - The Hong Kong Medical Association Community Network Exercise 
Prescription Courses (Session 5)
Organiser: The Hong Kong Medical Association, Speaker: Prof. Stanley HUI/ Mr. Sam 
WONG, Venue: HKMA Wanchai Premises, 5/F, Duke of Windsor Social Service 
Building, 15 Hennessy Road, Wanchai, HK
1:00 pm
SAT
Ms. Clara Tsang
Tel: 2354 2440
2 CME points 8
Refresher Course for Health Care Providers 2012/2013
Organisers: Hong Kong Medical Association, HK College of Family Physicians & 
HA-Our Lady of Maryknoll Hospital, Speaker: Dr. Hui Pak Kwan, Venue: Training 
Room II, 1/F, OPD Block, Our Lady of Maryknoll Hospital, 118 Shatin Pass Road, 
Wong Tai Sin, Kowloon
2:30 pm
TUE
Miss Candice TONG
Tel: 2527 8285
1 CME point11
HKMA Kowloon West Community Network - Lecture Series on Allergic Diseases 
(Session 3) - Asthma and Allergic Rhinitis in Paediatrics
Organiser: HKMA Kowloon West Community Network, Chairman: Dr. LEUNG Gin 
Pang, Speaker: Dr. LEE Qun Ui, Venue: Crystal Room I-III, 30/F, Panda Hotel, 3 Tsuen 
Wah Street, Tsuen Wan, NT
1:00 pm
1:30 pm
WED
Ms. Sandy LEE
Tel: 2377 9801
1.5 CME points 5
HKMA Shatin Doctors Network– Practical Approach to Common Facial Skin Diseases
Organiser: HKMA Shatin Doctors Network, Chairman: Dr. MAK Wing Kin, Speaker: 
Dr. KU Lap Shing, Simon, Venue: Star Seafood Floating Restaurant, Shatin
1:15 pm
FRI
Mr. Chris PAU
Tel: 9736 7830
2 CME points 7
HKMA Shatin Doctors Network – The unique role of dopamine and nor-adrenaline in 
treatment of depression
Organiser: HKMA Shatin Doctors Network, Chairman: Dr. MAK Wing Kin, Speaker: 
Dr. LAI Tai Sum, Tony, Venue: Lei Garden Restaurant, 6/F, New Town Plaza Phase 1
1:00 pm
SUN
Ms. Nadia HO 
Tel: 2527 82859
HKMAPS Photo Sharing
Organiser: Hong Kong Medical Association, Speaker: Dr. Amy Pang, Venue: HKMA 
Wanchai Premises, 5/F, Duke of Windsor Social Service Building, 15 Hennessy Road, 
Wanchai, HK
2:00 pm
WED
Dr. Gilberto LEUNG
Tel: 2255 3368
1.5 CME points12 Hong Kong  Neurosurgical Society Monthly Academic Meeting – flow Regulator: Development of Shunt ValvesOrganiser: Hong Kong Neurosurgical Society, Chairman: Dr. Wilson Ho, Speaker: Dr. 
Wong Ping Hong, Derek, Venue: Seminar Room, Ground Floor, Block A, Queen 
Elizabeth Hospital
7:30 pm
Miss Phoebe WONG
Tel: 2527 8285
HKMA Tennis Tournament 2012
Organiser: The Hong Kong Medical Association, Venue: Kowloon Tong Club
8:00 pm
Mr. Alan LAW
Tel: 2527 8285
HKMA CME – Certificate Course for GPs 2012
Organiser: The Hong Kong Medical Association, Venue: TKO
1:00 pm
Dr. Or Chi Kong
Tel: 2911 0022
2.5 CME points 
HKMA CME – Laser Forum 2012 (Seminar on Cosmetic Surgery)
Organisers: HK Surgical Laser Assn, Hong Kong Association of Cosmetic Surgery, 
Hong Kong Medical Association, Hong Kong Dental Association & Association of 
Hong Kong Nursing Staff, Chairmen: Dr. Or Chi Kong & Dr. Ying Shun Yuen, Clement, 
Speakers: Dr. Lam Chuk Kwan, Stephanie, Dr. Ho Wai Sun, Wilson, Dr. Hsieh Cheung 
Philip, Dr. Kwan Kin Hung & Dr. Ho Wai Sun, Wilson, Venue: Seminar Room, Mezz 
Floor, Hospital Authority, 147B Argyle Road, Kowloon
Hong Kong College of 
Paediatricians
Tel: 2871 8773
3 CME points (Category A)
2012 Paediatric Update No.3 – Paediatric Neurology
Organiser: Hong Kong College of Paediatricians, Chairmen: Dr. Sik Nin Wong & Dr. 
Shun Ping Wu, Speakers; Dr. Shun Ping Wu, Dr. Sheila Wong, Dr. Louis CK Ma & Dr. 
Sophelia Chan, Venue: Pao Yue Kong Auditorium, G/F, HK Academy of Medicine 
Jockey Club Building, 99 Wong Chuk Hang Road, Aberdeen, Hong Kong
Miss Phoebe WONG
Tel: 2527 8285
Joint Professional Volleyball Tournament 2012
Organiser: The Hong Kong Medical Association, Venue: Sun Yat Sen Memorial Park 
Sports Centre
SUN
Dr. Or Chi Kong
Tel: 2911 0022
5 CME points 2
HKMA CME– Laser Forum 2012 (Certificate Course- Frontiers in Laser Surgery and Safety)
Organisers: HK Surgical Laser Assn, Hong Kong Association of Cosmetic Surgery, 
Hong Kong Medical Association, Hong Kong Dental Association & Association of Hong 
Kong Nursing Staff, Chairmen: Dr. Johnny Wong, Dr. Chow Pak Chin, Dr. Wong Wai 
Hong & Dr. Chow Ka Yuen, Leo, Speakers: Dr. Seto S K Ryan, Dr. Johnny Wong, Dr. 
Chen Ngan Ivan, Dr. Cheng Chak Kwan, Arthur, Dr. Chong Kam Lung, Kelvin, Dr. 
Chan Wai Man; Mr. Au Tat Lun, Alun, Dr. Chan Pui Yin, Nicola, Dr. Hui Shiu Kee & 
Dr. Wong Mon Ching, Venue: Lecture Theatre, Mezz Floor, Hospital Authority, 147B 
Argyle Road, Kowloon
9:00 am
7:00 pm
Miss Phoebe WONG
Tel: 2527 8285
HKMA Tennis Tournament 2012
Organiser: The Hong Kong Medical Association, Venue: Kowloon Tong Club
8:00 pm
HKMA CME Dept.
Tel: 2527 8452
2 CME points 
HKMA CME - The Hong Kong Medical Association Community Network Exercise 
Prescription Courses (Session 5)
Organisers: Hong Kong Medical Association & Department of Health, Speaker: Prof. 
Stanley HUI/ Mr. Sam WONG, Venue: Chiu Chow Garden, Shops 001-003, 1/F, Uptown 
Plaza, Tai Po, NT
1:30 pm
Ms. Nancy CHAN 
Tel: 2527 8898 
FMSHK Officers’ Meeting
Organiser: The Federation of Medical Societies of Hong Kong,   Venue: Gallop, 2/F., 
Hong Kong Jockey Club Club House, Shan Kwong Road, Happy Valley, Hong Kong 
8:00 pm
Ms. Christine WONG
Tel: 2527 8285
HKMA Council Meeting
Organiser: The Hong Kong Medical Association, Chairman: Dr. TSE Hung Hing, 
Venue: HKMA Head Office (5/F., Duke of Windsor Social Service Building, 15 
Hennessy Road, Hong Kong)
8:00 pm
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MON
Ms. Nancy CHAN 
Tel: 2527 889831 FMSHK Annual Dinner 2012Organiser: The Federation of Medical Societies of Hong Kong, Venue: Run Run Shaw Hall, the Hong Kong Academy of Medicine Jockey Club Building
7:00 pm
Ms. Candy YUEN
Tel: 2527 8285
HKMA Annual Ball 2012
Organiser: The Hong Kong Medical Association, Venue: Grand Ballroom, Conrad Hong 
Kong
8:00 pm
Date  / Time Function Enquiry / Remarks
THU
Mr. Alan LAW
Tel: 2527 8285
1 CME point13
HKMA Kowloon East Community Network- Advance Treatment in Low Back Pain
Organiser: HKMA-KLN East Community Network, Chairman: Dr. AU Ka Kui, Gary, 
Speaker: Dr. Sun Kin Wai, Kelvin, Venue: Lei Garden Restaurant, Shop No. L5-8, APM 
Millennium City 5, 418 Kwun Tong Road, Kwun Tong
1:00 pm
SUN
Miss Phoebe WONG
Tel: 2527 828516
Joint Professional Volleyball Tournament 2012
Organiser: The Hong Kong Medical Association, Venue: Sun Yat Sen Memorial Park 
Sports Centre
6:00 pm
Miss Phoebe WONG
Tel: 2527 8285
HKMA Tennis Tournament 2012
Organiser: The Hong Kong Medical Association, Venue: Kowloon Tong Club
8:00 pm
HKMA CME Dept.
Tel: 2527 8452
1 CME point
HKMA Structured CME Programme with Hong Kong Sanatorium & Hospital Year 
2012– Review and Updates on Refractive Error
Organiser: The Hong Kong Medical Association, Speaker: Dr. Fan Shu Ping, Dorothy, 
Venue: HKMA Dr. Li Shu Pui Professional Education Centre, 2/F, Chinese Club 
Building, 21-22 Connaught Road, Central, Hong Kong
2:00 pm
FRI
Miss Candice TONG
Tel: 2527 8285
1 CME point14
HKMA Yau Tsim Mong Community Network - BPH Management: Not Only Focus on 
Prostate?
Organiser: HKMA Yau Tsim Mong Community Network, Chairman: Dr. LAM Tzit 
Yuen, David, Speaker: Dr. SO Chun, Venue: Eaton Smart,. Hong Kong, YMT
1:00 pm
TUE
Ms. Joyce
Tel: 2664 3808
1 CME point18
HKMA Tai Po Community Network - Common Pitfalls in Management of Breast Disease
Organiser: HKMA-Tai Po Community Network, Speaker: Dr. Ho Nga Sze, Venue: 
Chiuchow Garden Restaurant, 1/F Uptown Plaza, Tai Po
1:45 pm
THU
Mr. Alan LAW
Tel: 2527 8285
1 CME point20
HKMA CME – Certificate Course for GPs 2012
Organiser: Hong Kong Medical Association, HA-United Christian Hospital & HK 
College of Family Physicians, Chairman: Dr. Leung Man Fuk, Speaker: Dr. Lin Shek 
Ying, Venue: East Ocean Seafood Restaurant, Shop 137, 1/F, Metro City Plaza 3, Mau 
Yip Road, Tseung Kwan O, Kowloon
1:00 pm
SAT
Miss Candice TONG
Tel: 2527 828529 HKMA Hong Kong East Community Network – Latest Update in GERD TreatmentOrganiser: HKMA Hong Kong East Community Network, Venue: HKMA Head Office (5/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Hong Kong)
1:00 pm
Ms. Nancy CHAN 
Tel: 2527 8898 
FMSHK Executive Committee Meeting
Organiser: The Federation of Medical Societies of Hong Kong, Venue: Council Chamber, 
4/F, Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong
8:00 pm
WED
Mr. Alan LAW
Tel: 2527 8285
1 CME point19
HKMA Central, Western & Southern Community Network - Chronic Hepatitis B: 
Review and Treatment
Organiser: HKMA-Central, Western & Southern Community Network, Chairman: Dr. 
YIK Ping Yin, Speaker: Dr. Wong Chun Yu, Benjamin, Venue: HKMA Central Premises, 
2/F. Chinese Club Building, 21-22 Connaught Road Central, HK
1:00 pm
SUN
Miss Phoebe WONG
Tel: 2527 828523
HKMA Tennis Tournament 2012
Organiser: The Hong Kong Medical Association, Venue: Kowloon Tong Club
8:00 pm
SUN
Miss Phoebe WONG
Tel: 2527 828530 HKMA Tennis Tournament 2012Organiser: The Hong Kong Medical Association, Venue: Kowloon Tong Club8:00 pm
Ms. Cindy LUI
Tel: 2969 5202
1.5 CME points 
HKMA Shatin Doctors Network - Review and Update on GERD
Organiser: HKMA-Shatin Doctors Network, Chairman: Dr. MAK Wing Kin, Speaker: 
Dr. SZE Wan Chee, Venue: Jasmine Room, Level 2, Royal Park Hotel, Shatin
1:30 pm
Mr. Jas CHEUNG
Tel: 9455 9816
1 CME point 
HKMA Shatin Doctors Network - Achieving Glycemic Control in Patients with Type 2 
Diabetes
Organiser: HKMA-Shatin Doctors Network, Chairman: Dr. MAK Wing Kin, Speaker: 
Dr. CHEUGN Fu Keung, Venue: Royal Park Hotel, Shatin
1:30 pm
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Answer to Dermatological Quiz
1.
2.
This middle aged man developed this rapidly enlarging 
ulcer over a few weeks.  The ulcer showed an erythematous 
violaceous slightly undermined edge over a purulent 
granulomatous base with yellowish discharge.  Together 
with the history of inflammatory bowel disease and the 
lack of response to antibiotics, the clinical diagnosis of 
pyoderma gangrenosum (PG) should be considered. 
Differential diagnoses should include chronic ulcer due 
to infections (e.g caused by streptococcal infection, rarely 
due to deep mycoses such as chromoblastomycosis, or 
atypical and typical mycobacterial infection), vasculitis 
(such as cutaneous polyarteritis nodosa, granulomatous 
vasculitis such as Wegener’s granulomatosis), autoimmune 
connective tissue disease (such as Behcet’s disease), and 
malignancy (such as squamous cell carcinoma).  The 
diagnosis of PG is by exclusion of other differential 
diagnoses, usually by repeated cultures and skin biopsies. 
In our patient, the histological finding and culture results 
helped to rule out these differential diagnoses.
Pyoderma gangrenosum is commonly associated with 
inflammatory bowel diseases (as shown in our patient, 
20-30%), arthritis (such as rheumatoid arthritis, 20%) 
and haematological diseases (such as acute and chronic 
myelogenous leukaemia and monoclonal gammopathy, 
up to 15%). Thorough work up of gastrointestinal studies, 
haematological studies, and radiological studies as guided 
by symptoms are indicated to exclude these associations. 
Oral prednisolone (0.5-1mg/kg as tailored to the disease 
severity) gives most predictable effective response.  Steroid 
sparing agents such as cyclosporine and thalidomide 
can be considered for refractory disease that requires 
prolonged high doses of systemic steroid.  For individuals 
with concomitant Crohn’s disease, such as our patient, 
infliximab has been used with success.
Dr. Ka-ho LAU
MBBS(HK), FRCP(Edin, Glasg), FHKCP, FHKAM(Med)
Yaumatei Dermatology Clinic, Social Hygiene Service
 The Federation of Medical Societies of Hong Kong
 4/F Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, HK
 Tel: 2527 8898           Fax: 2865 0345
President
Dr. LO See-kit, Raymond    勞思傑醫生
1st Vice-President
Prof. CHAN Chi-fung, Godfrey 陳志峰教授
2nd Vice-President
Dr. CHAN Sai-kwing 陳世烱醫生
Hon. Treasurer
Mr. LEE Cheung-mei, Benjamin  李祥美先生
Hon. Secretary
Dr. NG Yin-kwok  吳賢國醫生
Immediate Past President
             Dr. FONG To-sang, Dawson                      方道生醫生
Executive Committee Members
Dr. CHAN Chun-kwong, Jane 陳真光醫生
Dr. CHAN Hau-ngai, Kingsley 陳厚毅醫生
Prof. CHIM Chor-sang, James 詹楚生教授
Dr. FONG Yuk-fai, Ben 方玉輝醫生
Dr. HUNG Che-wai, Terry 洪致偉醫生
Ms. KU Wai-yin, Ellen 顧慧賢女士
Dr. LO Sze-ching, Susanna 盧時楨醫生
Dr. MAN Chi-wai 文志衛醫生
Dr. MOK Chun-on 莫鎮安醫生
Dr. WONG Mo-lin, Maureen 黃慕蓮醫生
Ms. YAP Woan-tyng, Tina 葉婉婷女士
Dr. YU Chau-leung, Edwin 余秋良醫生
Dr. YUEN Shi-yin, Nancy 袁淑賢醫生
Dr. YUNG Shu-hang, Patrick 容樹恆醫生
Founder Members
British Medical Association (Hong Kong Branch)
英 國 醫 學 會 ( 香 港 分 會 )
President
Dr. LO See-kit, Raymond  勞思傑醫生
Vice-President
Dr. WU, Adrian  鄔揚源醫生
Hon. Secretary
Dr. HUNG Che-wai, Terry   洪致偉醫生
Hon. Treasurer
Dr. Jason BROCKWELL  
Council Representatives
Dr. LO See-kit, Raymond  勞思傑醫生
Dr. CHEUNG Tse-ming 張子明醫生
Tel:  2527 8898        Fax: 2865 0345
The Hong Kong Medical Association
香 港 醫 學 會
President
Dr. TSE Hung-hin   謝鴻興醫生
Vice- Presidents
Dr. CHAN Yee-shing, Alvin 陳以誠醫生
Dr. CHOW Pak-chin 周伯展醫生
Hon. Secretary
Dr. LAM Tzit-yuen 林哲玄醫生
Hon. Treasurer
Dr. LEUNG Chi-chiu 梁子超醫生
Council Representatives
Dr. CHAN Yee-shing  陳以誠醫生
Dr. CHOW Pak-chin 周伯展醫生
Chief Executive
Mrs. LEUNG, Yvonne 梁周月美女士
Tel: 2527 8285 (General Office)
       2527 8324 / 2536 9388  (Club House in Wanchai / Central)
Fax: 2865 0943 (Wanchai), 2536 9398 (Central)
Email: hkma@hkma.org   Website: http://www.hkma.org
The HKFMS Foundation Limited  香港醫學組織聯會基金  
Board of Directors
President
Dr. LO See-kit, Raymond 勞思傑醫生
1st Vice-President
Prof. CHAN Chi-fung, Godfrey 陳志峰教授
2nd Vice-President
Dr. CHAN Sai-kwing  陳世烱醫生
Hon. Treasurer
Mr. LEE Cheung-mei, Benjamin  李祥美先生
Hon. Secretary
Dr. NG Yin-kwok   吳賢國醫生
Directors
Mr. CHAN Yan-chi, Samuel 陳恩賜先生
Prof. CHIM Chor-sang, James 詹楚生教授
Ms. KU Wai-yin, Ellen 顧慧賢女士
Dr. WONG Mo-lin, Maureen 黃慕蓮醫生
Dr. YU Chak-man, Aaron 余則文醫生
Dermatological Quiz


